Bohdan M, Kowalczys A, Mickiewicz A, Gruchała M, Lewicka E. Cancer therapy-related cardiovascular complications in clinical practice: current perspectives. J Clin Med Res [Internet]. 2021;10(8). https://doi.org/10.3390/jcm10081647.

Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17(5):353–77.

Article  PubMed  CAS  Google Scholar 

Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491–500.

Article  PubMed  Google Scholar 

Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, et al. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol. 2018;72(6):697–8.

Article  PubMed  PubMed Central  Google Scholar 

Lampson B, Yu L, Barrientos J, Jacobsen E, Banerji V, Jones J, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib [Internet]. Vol. 16, Clinical Lymphoma Myeloma and Leukemia. 2016. S52. https://doi.org/10.1016/j.clml.2016.07.075.

Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular Toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–78.

Article  PubMed  CAS  Google Scholar 

Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bhat SA, Gambril JA, Azali L, Chen ST, Rosen L, Palettas M, et al. Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood [Internet]. 2022; https://doi.org/10.1182/blood.2022016953.

Beyer A, Ganti B, Majkrzak A, Theyyunni N. A Perfect Storm: Tyrosine kinase inhibitor-associated polymorphic ventricular tachycardia. J Emerg Med. 2017;52(4):e123–7.

Article  PubMed  Google Scholar 

Wallace N, Wong E, Cooper D, Chao H. A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin Case Rep. 2016;4(12):1120–1.

Article  PubMed  PubMed Central  Google Scholar 

Tomcsányi J, Nényei Z, Mátrai Z, Bózsik B. Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia. JACC: Clin Electrophysiol. 2016;2(7):847–9.

Google Scholar 

Prashar A, Ilsar R, Roncolato F, Hopkins A. Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia. HeartRhythm Case Rep. 2020;6(10):770–3.

Article  PubMed  PubMed Central  Google Scholar 

Spechbach H, Morel P, IngLorenzini K, Besson M, Gétaz L, Sunthorn H, et al. Reversible ventricular arrythmia induced by dasatinib. Clin Case Rep. 2013;1(1):20–5.

Article  PubMed  PubMed Central  Google Scholar 

Madgula AS, Singh M, Almnajam M, Pickett CC, Kim AS. Ventricular tachycardia storm in a patient treated with ibrutinib for Waldenstrom macroglobulinemia. Cardio Oncol. 2020;2(3):523–6.

Google Scholar 

Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020;147(11):3160–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Du B, Chakraborty P, Azam MA, Massé S, Lai PFH, Niri A, et al. Acute effects of ibrutinib on ventricular arrhythmia in spontaneously hypertensive rats. JACC: Cardio Oncol. 2020;2(4):614–29.

Google Scholar 

Tuomi JM, Xenocostas A, Jones DL. Increased susceptibility for atrial and ventricular cardiac arrhythmias in mice treated with a single high dose of ibrutinib. Can J Cardiol. 2018;34(3):337–41.

Article  PubMed  Google Scholar 

Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, et al. Absorption, metabolism, and excretion of oral 14c radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015;43(2):289–97.

Article  PubMed  Google Scholar 

Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867.

Article  PubMed  Google Scholar 

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-391.

PubMed  Google Scholar 

Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111–21.

Article  PubMed  CAS  Google Scholar 

Madonna R, Pieragostino D, Cufaro MC, Del Boccio P, Pucci A, Mattii L, et al. Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. J Cell Mol Med. 2022;26(5):1380–91.

Article  PubMed  PubMed Central  CAS  Google Scholar